Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02135900 · ClinicalTrials.gov registry record · Phase 2
The Use of Heliox in Obstructive Sleep Apnea Syndrome
A Phase 2 study of Obstructive Sleep Apnea Syndrome, sponsored by Northwell Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT02135900 is a Phase 2 study of Obstructive Sleep Apnea Syndrome that has completed, run by Northwell Health. The registered enrollment target is 32 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02135900, a Phase 2 study of Obstructive Sleep Apnea Syndrome, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The goals of the project is to evaluate the effects of Heliox therapy on obstructive sleep apnea syndrome (OSAS).
Conditions Studied
Interventions
- DRUG Heliox
Study Locations (1)
New York
- Sleep center, Staten Island University Hospital - Staten Island
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2009-12 |
| Est. Completion | 2011-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02135900
The ClinicalTrials.gov registry entry for NCT02135900 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obstructive Sleep Apnea Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Heliox is the first listed.
NCT02135900 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02135900 about?
NCT02135900 is a clinical study titled "The Use of Heliox in Obstructive Sleep Apnea Syndrome". The goals of the project is to evaluate the effects of Heliox therapy on obstructive sleep apnea syndrome (OSAS).
What is the current status of trial NCT02135900?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2009-12. Estimated completion is 2011-04.
What conditions does trial NCT02135900 study?
This clinical trial studies the following conditions: Obstructive Sleep Apnea Syndrome.
What interventions are being tested in trial NCT02135900?
The interventions under investigation include: Heliox (DRUG).
Who is sponsoring clinical trial NCT02135900?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02135900 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obstructive Sleep Apnea Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.